Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Medium materiality6/10

APRE to present APR-1051 Phase 1 data at ENA 2026; biomarker expansion

Nov 4, 2026, 8:54 AM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The ENA 2026 data presentation and biomarker expansion represent a concrete near-term catalyst, while a healthier cash runway reduces dilution risk and supports ongoing trials, potentially triggering a modest near-term rerating for a small-cap oncology name like APRE.

AI summary

What happened, with direct paths to the underlying reporting

Aprea Therapeutics reports updated interim Phase 1 data for the oral WEE1 inhibitor APR-1051 to be showcased at ENA 2026 in Barcelona on November 20. The trial has grown to nine sites with Cyclin E IHC biomarker testing added to guide future patient selection. Cash and equivalents stood at $37.8 million as of September 30, 2026, with a cash runway expected into Q1 2028, underpinning near-term execution risk.

Updated interim Phase 1 data for APR-1051 to be presented at ENA 2026.
Trial expanded to nine sites; Cyclin E immunohistochemistry (IHC) biomarker testing in place.
Cash and equivalents: $37.8 million as of Sep 30, 2026; runway into Q1 2028.
Upcoming ENA presentation could act as a near-term catalyst for APRE.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.